NBIX - Neurocrine Biosciences Non-GAAP EPS of $0.30 misses by $0.29 revenue of $310.6M beats by $6.53M; reaffirms FY22 guidance

Neurocrine Biosciences press release (NASDAQ:NBIX): Q1 Non-GAAP EPS of $0.30 misses by $0.29. Revenue of $310.6M (+31.3% Y/Y) beats by $6.53M. At March 31, 2022, the Company had cash, cash equivalents and marketable securities of $1.2 billion.  Reiterated 2022 INGREZZA Sales and Operating Expense Guidance: INGREZZA Net Product Sales of $1,250M-$1,350M; Non-GAAP R&D expense of $325-$360M; Non-GAAP SG&A expense of $605M-$620M.

For further details see:

Neurocrine Biosciences Non-GAAP EPS of $0.30 misses by $0.29, revenue of $310.6M beats by $6.53M; reaffirms FY22 guidance